Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

Phase: N/A Priority: Normal
NCT ID: NCT04847102 Org: User:
Start: 07/22/21 End: 05/30/23 Due: 05/30/24

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Phase: N/A Priority: Normal
NCT ID: NCT04450498 Org: User:
Start: 12/23/20 End: 07/30/21 Due: 07/30/22

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05396573 Org: User:
Start: 07/31/22 End: 07/31/23 Due: 07/31/24

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05394012 Org: User:
Start: 12/31/22 End: 06/30/23 Due: 06/30/24

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Phase: N/A Priority: Normal
NCT ID: NCT05934890 Org: User:
Start: 11/23/23 End: 02/28/26 Due: 02/28/27

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Phase: N/A Priority: Normal
NCT ID: NCT02736240 Org: User:
Start: 04/08/16 End: 12/03/17 Due: 12/03/18

Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

Phase: N/A Priority: Normal
NCT ID: NCT02285036 Org: User:
Start: 09/30/12 End: 05/31/13 Due: 05/31/14

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Phase: N/A Priority: Normal
NCT ID: NCT04236960 Org: User:
Start: 07/17/18 End: 11/28/19 Due: 11/28/20